Cover Image
市場調查報告書

Immunocore Limited - 產品平台分析

Immunocore Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256078
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
Immunocore Limited - 產品平台分析 Immunocore Limited - Product Pipeline Review - 2015
出版日期: 2015年05月29日 內容資訊: 英文 33 Pages
簡介

Immunocore Limited是總公司設立於英國的生物科技企業,正從事癌症以及其他重大疾病的生技藥品之開發。該公司產品──IMCgp100是末期惡性黑色素瘤患者的治療藥。除此以外尚提供癌症,感染疾病,自體免疫疾病等治療藥。

本報告提供Immunocore Limited的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Immunocore Limited的基本資料

  • Immunocore Limited概要
  • 主要資訊
  • 企業資料

Immunocore Limited:R&D概要

  • 主要的治療範圍

Immunocore Limited:開發平台分析

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Immunocore Limited:開發中產品概況

  • 臨床階段的開發中產品
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Immunocore Limited:藥物簡介

  • MCgp100
  • MCmage1
  • Recombinant Protein for Cancer
  • Recombinant Protein for HCV
  • Recombinant Protein for Prostate Cancer
  • Recombinant Protein for Type I Diabetes
  • Recombinant Protein to Antagonize CD3
  • Recombinant Protein to Inhibit Gag for HIV

Immunocore Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Immunocore Limited:最近的開發平台資訊

Immunocore Limited:暫停開發中的計劃

Immunocore Limited:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07097CDB

Summary

Global Markets Direct's, 'Immunocore Limited - Product Pipeline Review - 2015', provides an overview of the Immunocore Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immunocore Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Immunocore Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Immunocore Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Immunocore Limited's pipeline products

Reasons to buy

  • Evaluate Immunocore Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Immunocore Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Immunocore Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Immunocore Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immunocore Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Immunocore Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Immunocore Limited Snapshot
    • Immunocore Limited Overview
    • Key Information
    • Key Facts
  • Immunocore Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Immunocore Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Immunocore Limited - Pipeline Products Glance
    • Immunocore Limited - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Immunocore Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Immunocore Limited - Drug Profiles
    • IMCgp100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMCmage1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for HCV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Prostate Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Type I Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Antagonize CD3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Inhibit Gag for HIV
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Immunocore Limited - Pipeline Analysis
    • Immunocore Limited - Pipeline Products by Target
    • Immunocore Limited - Pipeline Products by Route of Administration
    • Immunocore Limited - Pipeline Products by Molecule Type
    • Immunocore Limited - Pipeline Products by Mechanism of Action
  • Immunocore Limited - Recent Pipeline Updates
  • Immunocore Limited - Dormant Projects
  • Immunocore Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Immunocore Limited, Key Information
  • Immunocore Limited, Key Facts
  • Immunocore Limited - Pipeline by Indication, 2015
  • Immunocore Limited - Pipeline by Stage of Development, 2015
  • Immunocore Limited - Monotherapy Products in Pipeline, 2015
  • Immunocore Limited - Partnered Products in Pipeline, 2015
  • Immunocore Limited - Partnered Products/ Combination Treatment Modalities, 2015
  • Immunocore Limited - Phase I, 2015
  • Immunocore Limited - Preclinical, 2015
  • Immunocore Limited - Discovery, 2015
  • Immunocore Limited - Pipeline by Target, 2015
  • Immunocore Limited - Pipeline by Route of Administration, 2015
  • Immunocore Limited - Pipeline by Molecule Type, 2015
  • Immunocore Limited - Pipeline Products by Mechanism of Action, 2015
  • Immunocore Limited - Recent Pipeline Updates, 2015
  • Immunocore Limited - Dormant Developmental Projects,2015

List of Figures

  • Immunocore Limited - Pipeline by Top 10 Indication, 2015
  • Immunocore Limited - Pipeline by Stage of Development, 2015
  • Immunocore Limited - Monotherapy Products in Pipeline, 2015
  • Immunocore Limited - Pipeline by Top 10 Target, 2015
  • Immunocore Limited - Pipeline by Top 10 Route of Administration, 2015
  • Immunocore Limited - Pipeline by Top 10 Molecule Type, 2015
  • Immunocore Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top